What is OTLC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OTLC?

P/E (TTM) is 0.04 and 52-week range is $0.02 to $0.11 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OTLC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OTLC?

The company profile lists revenue (TTM) near $222K, net income (TTM) near $344K, EPS (TTM) near $0.56 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Oncotelic Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Agoura Hills, California, US, 443.6M shares outstanding, ISIN US6283411097 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is headquartered in Agoura Hills, California and currently employs 38 full-time employees. The firm has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Website

www.oncotelic.com/

IPO

1993-08-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)